Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS.

Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10.

PMID:
30530751
2.

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS.

Leukemia. 2015 Mar;29(3):647-59. doi: 10.1038/leu.2014.233. Epub 2014 Aug 5. Erratum in: Leukemia. 2016 Apr;30(4):1003-4.

PMID:
25092142
3.

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).

Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75. doi: 10.1073/pnas.1416389112. Epub 2014 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6254-6. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6258-60.

4.

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.

Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS.

Leukemia. 2000 Mar;14(3):419-26.

PMID:
10720136
5.

Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.

Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet JG, Choppin J.

Eur J Immunol. 1997 Aug;27(8):2066-72.

PMID:
9295046
6.

Chronic myeloid leukemia as an immunological target.

Lim SH, Coleman S.

Am J Hematol. 1997 Jan;54(1):61-7. Review.

7.
8.

Specific human cellular immunity to bcr-abl oncogene-derived peptides.

Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA.

Blood. 1996 May 1;87(9):3587-92.

9.

HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.

Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M, van Biezen JH, Hermans J, Willemze R, Niederwieser D.

Blood. 1999 Jun 1;93(11):3863-5.

10.
11.

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S.

Blood. 2015 Sep 3;126(10):1203-13. doi: 10.1182/blood-2015-04-640532. Epub 2015 Jul 2. Erratum in: Blood. 2015 Oct 22;126(17):2072-3.

12.

BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.

Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC, Ossendorp F, Melief CJ.

Leukemia. 2006 Oct;20(10):1738-50. Epub 2006 Aug 24.

PMID:
16932347
13.

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.

Hughes A, Yong ASM.

Front Immunol. 2017 Apr 24;8:469. doi: 10.3389/fimmu.2017.00469. eCollection 2017. Review.

14.

Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?

Riley CL, Mathieu MG, Clark RE, McArdle SE, Rees RC.

Cancer Immunol Immunother. 2009 Sep;58(9):1489-99. doi: 10.1007/s00262-009-0675-x. Epub 2009 Mar 4. Review.

PMID:
19259670
15.

Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.

Cai A, Keskin DB, DeLuca DS, Alonso A, Zhang W, Zhang GL, Hammond NN, Nardi V, Stone RM, Neuberg D, Sidney J, Brusic V, Wu CJ.

Clin Cancer Res. 2012 Oct 15;18(20):5761-72. doi: 10.1158/1078-0432.CCR-12-1182. Epub 2012 Aug 21.

16.

HLA CW3 and HLA CW4 have a protective effect on acquisition of chronic myeloid leukemia on Mexican patients.

Rosas-Cabral A, Irigoyen L, Alvarado L, Vela-Ojeda J, Ayala-Sánchez M, Tripp-Villanueva F, Sánchez E, Gonzalez-Llaven J, Gariglio P.

Rev Invest Clin. 2003 Jul-Aug;55(4):423-8.

PMID:
14635607
17.
18.

Coexistence of p210BCR-ABL and CBFβ-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.

Wang YY, Ding WJ, Jiang F, Chen ZX, Cen JN, Qi XF, Liang JY, Liu DD, Pan JL, Chen SN.

Oncol Lett. 2017 Nov;14(5):5171-5178. doi: 10.3892/ol.2017.6812. Epub 2017 Aug 24.

19.

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.

Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B.

Blood. 2008 Sep 1;112(5):1876-85. doi: 10.1182/blood-2008-04-150045. Epub 2008 Jun 30.

20.

Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.

Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G.

Cancer Res. 2007 Jun 1;67(11):5300-7.

Supplemental Content

Support Center